Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Viewpoint
Nature Reviews Endocrinology 1, 4–5 (1 November 2005) | doi:10.1038/ncpendmet0016
Mineralocorticoid-receptor blockade, hypertension and heart failure
Abstract
Hypertension and heart failure can be treated with mineralocorticoid-receptor antagonists, although therapy is associated with an increased incidence of hyperkalemia. Data from three influential clinical trials—RALES, EPHESUS and 4E—are described and the findings discussed within the context of mineralocorticoid-receptor biology.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
